No annual revenue total was found in ATOSSA THERAPEUTICS, INC.'s SEC filings.
Atossa Therapeutics, Inc. (ATOS) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$29.8 million.
Revenue
—
Net income (TTM)
$-8.81M
+47.0% vs year-ago TTM
Operating cash flow (TTM)
$-35.77M
-43.0% vs year-ago TTM
Free cash flow (TTM)
$-35.78M
-42.9% vs year-ago TTM
EPS
$-4.04
-32.9% vs prior year
Dividend per share
None
Shares outstanding
8.61M
-93.3% vs prior year
Net cash
$110.89M
FY 2022
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ATOS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Seattle, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1488039
- Former names
- ATOSSA GENETICS INC (until Nov 13, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$37.1M | -$27.6M | -$31.4M | -$27.7M | -$20.5M |
| Net income | -$34.8M | -$25.5M | -$30.1M | -$27.0M | -$20.6M |
| Diluted EPS | -$4.04 | -$3.04 | -$0.24 | — | — |
| Operating cash flow | -$29.8M | -$21.0M | -$20.9M | -$20.8M | -$16.5M |
| Free cash flow | -$29.8M | -$21.0M | -$21.0M | -$20.8M | -$16.5M |
| Total assets | $47.6M | $76.4M | $96.3M | $123.5M | $141.3M |
| Total liabilities | $8.3M | $5.0M | $5.2M | $5.6M | $3.1M |
| Stockholders' equity | $39.4M | $71.5M | $91.0M | $118.0M | $138.1M |
| Cash and investments | $41.3M | $71.1M | $88.5M | $110.9M | $136.4M |
| Total debt | — | — | — | $0 | $0 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Change to shareholder rights, Other events
|
Oct 9, 2026 | Oct 8, 2026 |
| 8-K |
Current report
Other events
|
Sep 29, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 18, 2026 | Sep 18, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2026 | Aug 7, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement
|
Jun 11, 2026 | Jun 10, 2026 |
All 641 Atossa Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.